Equities

Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • Revenue in USD (TTM)52.67bn
  • Net income in USD11.05bn
  • Incorporated1942
  • Employees90.20k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amgen, Inc.22.94bn8.39bn128.32bn20.80k16.788.2712.465.5911.563.0431.5623.440.30791.386.671,102,837.0011.279.3913.1110.7182.4980.9636.5931.043.6028.720.694738.42-0.61765.764.6213.21-0.736526.15
AbbVie Inc29.61bn9.96bn151.40bn29.00k15.3442.6113.085.116.223.9818.492.240.43874.535.631,021,103.0014.7911.5318.3014.8875.7877.2733.7122.441.106.880.91365.1510.068.9549.9710.999.70--
Merck & Co., Inc.40.73bn4.18bn168.22bn69.00k40.855.0019.154.131.530.572914.9412.500.4462.435.69590,217.404.606.005.787.4268.5665.1910.3214.521.1017.330.4186.640.7913-3.2227.40-4.13-0.68492.28
Pfizer Inc.52.67bn11.05bn220.24bn90.20k20.623.1412.684.181.833.598.7112.000.3161.415.74583,957.906.665.297.916.3079.2479.9021.0617.770.975219.740.366778.68-0.5263-0.784747.353.369.337.78
Data as of Jul 18 2018. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

25.33%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2018430.15m7.35%
SSgA Funds Management, Inc.as of 31 Mar 2018293.63m5.02%
BlackRock Fund Advisorsas of 31 Mar 2018285.31m4.88%
Northern Trust Investments, Inc.as of 31 Mar 201878.26m1.34%
JPMorgan Investment Management, Inc.as of 31 Mar 201870.74m1.21%
Wellington Management Co. LLPas of 31 Mar 201870.51m1.21%
Geode Capital Management LLCas of 31 Mar 201866.90m1.14%
T. Rowe Price Associates, Inc.as of 31 Mar 201864.97m1.11%
Massachusetts Financial Services Co.as of 31 Mar 201861.72m1.06%
State Farm Investment Management Corp.as of 31 Mar 201859.68m1.02%
More ▼
Data from 31 Mar 2018 - 31 Mar 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.